the side of every MH cart and in a binder in every OR. We also created
an MH cart policy so that we always had ready access to the many
supplies you need in an MH crisis (see "What's In Your MH Cart?" on
page 24).
Many of the steps on
the checklist will be
familiar to anyone
who has ever gone
through an MH drill.
But there are a couple
aspects that I should
highlight that are spe-
cific to our institution
and are key to our
quick response.
Our 5 MH carts
The MH cart is the
first thing that needs
to get to the bedside.
Like tanks on a battle-
field, we positioned
our 5 MH carts in
strategic locations
throughout the facili-
ty. We perform sur-
gery in 3 separate
locations, so we
placed a cart in each
surgery wing. We have
M a r c h 2 0 1 7 • O U T PA T I E N T S U R G E R Y. N E T • 3 9
Important Safety Information
The use of
The use of Revonto in the management of malignant hyperthermia crisis is not a substitute for previously
known supportive measures. These measures must be individualized, but it will usually be necessary to
discontinue the suspect triggering agents, attend to increased oxygen requirements, manage the
metabolic acidosis, institute cooling when necessary, monitor urinary output, and monitor for
electrolyte imbalance. Patients who receive i.v. dantrolene sodium preoperatively should have vital
signs monitored.
If patients judged malignant hype
If patients judged malignant hyperthermia susceptible are administered dantrolene sodium
preoperatively, anesthetic preparation must still follow a standard malignant hyperthermia susceptible
regimen, including the avoidance of known triggering agents. Monitoring for early clinical and
metabolic signs of malignant hyperthermia is indicated because attenuation of malignant
hyperthermia, rather than prevention, is possible.
Despite initial satisfacto
Despite initial satisfactory response to i.v. dantrolene there have been reports of fatality, which involve
patients who could not be weaned from dantrolene after initial treatment. The administration of i.v.
dantrolene is associated with loss of grip strength and weakness in the legs, as well as drowsiness and
dizziness. There have been reports of thrombophlebitis following administration of intravenous
dantrolene. Tissue necrosis secondary to extravasation has been reported. Injection site reactions
(pain, erythema, swelling), commonly due to extravasation, have been reported. Fatal and non-fatal
liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therap
liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy.
To report SUSPECTED ADVERSE REACTIONS contact US WorldMeds at 1-888-900-8796 or MEDWATCH at
1-800-FDA-1088 (1-800-332-1088) or http://www.FDA.gov/medwatch/.
To see the full prescribing information visit www.revonto.com.
© 2017. US WorldMeds, LLC. Revonto is a registered trademark of US WorldMeds, LLC.
REV-P91-0217
®
36
month
shelf
life*
Ready
to
administer
in
20
seconds
†
Are You Prepared for a CRISIS?
Visit www.revonto.com or call (877) 411-USWM (8796)
to learn more and to see the full Prescribing Information.
*from the date of manufacture
†
or until solution is clear